Kuehne+Nagel successfully helped Sinovac Biotech Ltd., a leading biopharmaceutical company in China fulfill its first Covid-19 vaccine shipment from Beijing, China to the Dominican Republic.
Sinovac is one of the global players in Covid-19 vaccine research and development. To date, the vaccine has been approved for emergency use or conditional marketing authorisation in more than 20 countries, including China, Brazil, Indonesia, Turkey and Chile.
The pilot shipment containing 768,000 vials of Covid-19 vaccine was stored in active temperature-controlled containers and arrived safely in Santo Domingo, the capital of the Dominican Republic, on February 23, benefitting its citizens just before its Independence Day. The shipment was closely monitored and compliant with the most stringent standards to guarantee product integrity.
Helen Yang, General Manager of Sinovac Biotech (Hong Kong) Limited said: “The Dominican Republic is 14,000 kilometers away from our factory in Beijing. During the ongoing pandemic, there are very few carriers connecting to this remote destination. However, Kuehne+Nagel responded to us with a feasible solution in just a short span of twelve hours. Even during the Chinese New Year holidays, the Kuehne+Nagel team was diligently preparing this shipment. We look forward to a collaborative partnership with Kuehne+Nagel.”
Siewloong Wong, President of Kuehne+Nagel Asia Pacific said: “We couldn’t be prouder to having started shipments of Sinovac Covid-19 vaccine. At Kuehne+Nagel, we leverage our global pharma & healthcare network and expertise to bring the Sinovac vaccine to the market. We truly appreciate the trust that Sinovac has bestowed upon us.”
Prior to this shipment, Kuehne+Nagel successfully fulfilled multiple crucial assignments for Sinovac, including an air charter from Beijing to Turkey for a door-to-door delivery of nearly a quarter-million flu vaccines. Kuehne+Nagel also helped with the shipment of Hepatitis A vaccine to Guatemala in South America as well as making nucleic acid detection kits available to people in Indonesia.
With offices all over the world, 240 GxP-certified operations and more than 3,000 dedicated pharma & healthcare specialists, Kuehne+Nagel has the capacity, the ability and the responsibility to play a vital role in the global distribution of COVID-19 vaccine.